Clinical efficacy of a vaccine-immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma

S. Centanni, F. Pregliasco, C. Bonfatti, C. Mensi, P. Tarsia, R. Guarnieri, L. Allegra

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Influenza is a leading cause of morbidity and mortality in patients with chronic respiratory diseases. This study compares two influenza prevention schemes in patients with chronic obstructive pulmonary disease and chronic asthma. We enrolled 66 patients, distributed as follows: Group A: 32 subjects treated with influenza vaccine; Group B: 34 patients treated with influenza vaccine and bacterial immunostimulant The rate of influenza episodes was recorded. Hemoagglutination inhibiting antibody titers for vaccine strains H1N1, H3N2, and B were determined at time 0 (prior to vaccination), and on days 30 and 90 following vaccination. We observed a lower rate of influenza episodes in Group B patients (8.82%) compared to Group A (31.25%) (p <0.05). At day 90 Group B patients presented higher geometric mean antibody titers for strains H1N1 (p = 0.07) and H3N2 (p = 0.08). Bacterial immunostimulants appear as possible adjuvants in the prevention of influenza episodes, and may prolong antibody response to influenza vaccine strains.

Original languageEnglish
Pages (from-to)273-278
Number of pages6
JournalJournal of Chemotherapy
Volume9
Issue number4
Publication statusPublished - 1997

Fingerprint

Combined Vaccines
Immunologic Adjuvants
Chronic Obstructive Pulmonary Disease
Human Influenza
Asthma
Influenza Vaccines
Vaccination
Antibodies
Antibody Formation
Chronic Disease
Vaccines
Morbidity
Mortality

Keywords

  • Asthma
  • Chronic obstructive pulmonary disease
  • COPD
  • Immunostimulants
  • Influenza
  • Prophylaxis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Clinical efficacy of a vaccine-immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma. / Centanni, S.; Pregliasco, F.; Bonfatti, C.; Mensi, C.; Tarsia, P.; Guarnieri, R.; Allegra, L.

In: Journal of Chemotherapy, Vol. 9, No. 4, 1997, p. 273-278.

Research output: Contribution to journalArticle

@article{2da64b761b224c9c94ba80eb25599dd4,
title = "Clinical efficacy of a vaccine-immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma",
abstract = "Influenza is a leading cause of morbidity and mortality in patients with chronic respiratory diseases. This study compares two influenza prevention schemes in patients with chronic obstructive pulmonary disease and chronic asthma. We enrolled 66 patients, distributed as follows: Group A: 32 subjects treated with influenza vaccine; Group B: 34 patients treated with influenza vaccine and bacterial immunostimulant The rate of influenza episodes was recorded. Hemoagglutination inhibiting antibody titers for vaccine strains H1N1, H3N2, and B were determined at time 0 (prior to vaccination), and on days 30 and 90 following vaccination. We observed a lower rate of influenza episodes in Group B patients (8.82{\%}) compared to Group A (31.25{\%}) (p <0.05). At day 90 Group B patients presented higher geometric mean antibody titers for strains H1N1 (p = 0.07) and H3N2 (p = 0.08). Bacterial immunostimulants appear as possible adjuvants in the prevention of influenza episodes, and may prolong antibody response to influenza vaccine strains.",
keywords = "Asthma, Chronic obstructive pulmonary disease, COPD, Immunostimulants, Influenza, Prophylaxis",
author = "S. Centanni and F. Pregliasco and C. Bonfatti and C. Mensi and P. Tarsia and R. Guarnieri and L. Allegra",
year = "1997",
language = "English",
volume = "9",
pages = "273--278",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "4",

}

TY - JOUR

T1 - Clinical efficacy of a vaccine-immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma

AU - Centanni, S.

AU - Pregliasco, F.

AU - Bonfatti, C.

AU - Mensi, C.

AU - Tarsia, P.

AU - Guarnieri, R.

AU - Allegra, L.

PY - 1997

Y1 - 1997

N2 - Influenza is a leading cause of morbidity and mortality in patients with chronic respiratory diseases. This study compares two influenza prevention schemes in patients with chronic obstructive pulmonary disease and chronic asthma. We enrolled 66 patients, distributed as follows: Group A: 32 subjects treated with influenza vaccine; Group B: 34 patients treated with influenza vaccine and bacterial immunostimulant The rate of influenza episodes was recorded. Hemoagglutination inhibiting antibody titers for vaccine strains H1N1, H3N2, and B were determined at time 0 (prior to vaccination), and on days 30 and 90 following vaccination. We observed a lower rate of influenza episodes in Group B patients (8.82%) compared to Group A (31.25%) (p <0.05). At day 90 Group B patients presented higher geometric mean antibody titers for strains H1N1 (p = 0.07) and H3N2 (p = 0.08). Bacterial immunostimulants appear as possible adjuvants in the prevention of influenza episodes, and may prolong antibody response to influenza vaccine strains.

AB - Influenza is a leading cause of morbidity and mortality in patients with chronic respiratory diseases. This study compares two influenza prevention schemes in patients with chronic obstructive pulmonary disease and chronic asthma. We enrolled 66 patients, distributed as follows: Group A: 32 subjects treated with influenza vaccine; Group B: 34 patients treated with influenza vaccine and bacterial immunostimulant The rate of influenza episodes was recorded. Hemoagglutination inhibiting antibody titers for vaccine strains H1N1, H3N2, and B were determined at time 0 (prior to vaccination), and on days 30 and 90 following vaccination. We observed a lower rate of influenza episodes in Group B patients (8.82%) compared to Group A (31.25%) (p <0.05). At day 90 Group B patients presented higher geometric mean antibody titers for strains H1N1 (p = 0.07) and H3N2 (p = 0.08). Bacterial immunostimulants appear as possible adjuvants in the prevention of influenza episodes, and may prolong antibody response to influenza vaccine strains.

KW - Asthma

KW - Chronic obstructive pulmonary disease

KW - COPD

KW - Immunostimulants

KW - Influenza

KW - Prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=0030847043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030847043&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 273

EP - 278

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 4

ER -